Novo NordiskSee all their emails

Novo post hoc analysis finds Wegovy 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026

A real announcement email from Novo Nordisk. Captured November 8, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo post hoc analysis finds Wegovy 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026 email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk press release announcing phase 3 ESSENCE post hoc analysis results for Wegovy in adults with MASH and BMI under 27 kg/m².

Standard corporate press release format with top-left company logo, bulleted key highlights, tabular clinical trial data, and contact details.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.